Literature DB >> 6283067

The affinity of morphine for its pharmacologic receptor in vivo.

R J Tallarida, A Cowan.   

Abstract

Morphine receptor affinity, an important constant in the classification of opiate receptors, has not yet been determined by a pharmacologic method. In the present study, we used a standard pharmacologic procedure, that of partial receptor occlusion, to make this determination in the rat utilizing the hot water (55 degrees C) tail flick test. The occluding compound was buprenorphine, a new narcotic antagonist analgesic that can bind to opiate receptors in an irreversible manner. When buprenorphine was given to rats in doses of 0.30 and 0.60 mg/kg (s.c.), 30 min before morphine (20-320 mg/kg s.c.) and 60 min before testing, it produced the theoretically predicted alterations in the morphine dose-response relation that are indicative of partial receptor blockade. The morphine receptor apparent dissociation constant (reciprocal of affinity) was calculated to be 1.7 X 10-6 M. This value is greater than those previously obtained in radiolabeled binding studies which have ranged from 3 to 27 X 10-9 M in the absence of sodium chloride to 1 to 5 X 10-7 M in the presence of sodium chloride. Used in this way, buprenorphine may be a valuable tool in the determination of apparent dissociation constants for other narcotic agonists.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6283067

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  4 in total

1.  Opioid receptor reserve in normal and morphine-tolerant guinea pig ileum myenteric plexus.

Authors:  C Chavkin; A Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1984-11       Impact factor: 11.205

2.  Buprenorphine/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers.

Authors:  Sandra D Comer; Ellen A Walker; Eric D Collins
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

3.  Use of a mu-antisense oligodeoxynucleotide as a mu opioid receptor noncompetitive antagonist in vivo.

Authors:  X H Chen; L Y Liu-Chen; R J Tallarida; E B Geller; J K de Riel; M W Adler
Journal:  Neurochem Res       Date:  1996-11       Impact factor: 3.996

4.  Clinical care of the HIV-infected drug user.

Authors:  R Douglas Bruce; Frederick L Altice
Journal:  Infect Dis Clin North Am       Date:  2007-03       Impact factor: 5.982

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.